Pfizer receives European approval for Oncology Biosimilar, RUXIENCE (rituximab) Medical Dialogues Bureau5 April 2020 2:15 PM ISTNew York: Pfizer Inc. has announced that the European Commission (EC) has approved RUXIENCE™ (rituximab), a monoclonal antibody (mAb) and biosimilar...
Pfizer gets USFDA nod for biosimilar to Rituximab Medical Dialogues Bureau25 July 2019 8:59 AM ISTRuxience is a mAb biosimilar to Rituxan which works by targeting a protein called CD20, which is present on the surface of B cells. Ruxience is...